Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses

Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits. Large vector doses also trigger an immune response as a significant fraction of the vectors fails to traffic efficiently...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zhong, Li, Li, Baozheng, Mah, Cathryn S., Govindasamy, Lakshmanan, Agbandje-McKenna, Mavis, Cooper, Mario, Herzog, Roland W., Zolotukhin, Irene, Warrington, Kenneth H., Weigel-Van Aken, Kirsten A., Hobbs, Jacqueline A., Zolotukhin, Sergei, Muzyczka, Nicholas, Srivastava, Arun
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2008
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2402387/
https://ncbi.nlm.nih.gov/pubmed/18511559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0802866105
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars